Condition
Unresectable Triple-Negative Breast Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Unresectable Triple-Negative Breast Carcinoma clinical trials that are recruiting, in United States. By phase: Phase 1 (3), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest Unresectable Triple-Negative Breast Carcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Safety of combining pidnarulex (CX-5461) with trastuzumab deruxtecan for HER2-positive, HER2-low/ultralow breast and other HER2-expressing solid tumors | Phase 1 | Boston, Massachusetts and 1 other locations | Recruiting | Aug 22, 2025 |
| Personalized tumor vaccine with checkpoint inhibitors for triple negative breast cancer | Phase 1 | Atlanta, Georgia and 3 other locations | Recruiting | Mar 21, 2024 |
| Using propranolol and pembrolizumab to treat resistant triple negative breast cancer | Phase 2 | Atlanta, Georgia and 1 other locations | Recruiting | Feb 23, 2023 |
| Combining ZEN003694 and Pembrolizumab with Standard Chemotherapy for Advanced Triple-Negative Breast Cancer | Phase 1 | Boston, Massachusetts and 5 other locations | Recruiting | Jun 21, 2022 |
| Personalized vaccine combined with pembrolizumab for advanced solid tumors | Phase 1/2 | Jacksonville, Florida | Recruiting | Mar 8, 2022 |
All recruiting trials (5)
-
Safety of combining pidnarulex (CX-5461) with trastuzumab deruxtecan for HER2-positive, HER2-low/ultralow breast and other HER2-expressing solid tumors
This trial tests whether adding pidnarulex to trastuzumab deruxtecan is safe and finds the best dose for adults with HER2-positive, HER2-low/ultralow, or other HER2-expressing advanced or metastatic breast and solid tumors.
-
Personalized tumor vaccine with checkpoint inhibitors for triple negative breast cancer
This phase I trial will test whether a personalized tumor membrane vesicle (TMV) vaccine, given alone or with pembrolizumab or ipilimumab, can boost immune response and help control disease in adults with triple negative breast cancer.
-
Using propranolol and pembrolizumab to treat resistant triple negative breast cancer
This study is testing if adding propranolol to pembrolizumab can help people with hard-to-treat triple negative breast cancer respond better to their treatment.
-
Combining ZEN003694 and Pembrolizumab with Standard Chemotherapy for Advanced Triple-Negative Breast Cancer
This study is testing a new combination of a targeted drug and immunotherapy with standard chemotherapy to see if it helps people with advanced triple-negative breast cancer.
-
Personalized vaccine combined with pembrolizumab for advanced solid tumors
This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.
Related topics
Quick answers
How many Unresectable Triple-Negative Breast Carcinoma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.